Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mavenclad is a prescription purine antimetabolite containing cladribine. It is indicated for relapsing forms of multiple sclerosis in adults, including relapsing-remitting disease and active secondary progressive disease. Due to its safety profile, it is usually considered after an inadequate response or intolerance to another multiple sclerosis treatment. Tablets contain 10 mg.
read more about mavenclad ...Cladribine is converted inside cells to active nucleotide metabolites that interfere with DNA synthesis and repair. This causes a reduction in lymphocytes, including B cells and T cells, that contribute to inflammatory activity in multiple sclerosis. The complete mechanism responsible for its therapeutic effects is not established.
Mavenclad treats adults with relapsing-remitting multiple sclerosis or active secondary progressive multiple sclerosis under current labeling. It is not recommended for clinically isolated syndrome. Patients undergo blood count testing, infection screening, pregnancy assessment, and cancer risk evaluation before treatment. Current malignancy, pregnancy, HIV infection, and certain active chronic infections are contraindications.
The recommended cumulative dose is 3.5 mg per kg by mouth over two yearly treatment courses, with 1.75 mg per kg per course. Each course contains two treatment cycles, and each cycle consists of one or two 10 mg tablets daily for four or five days according to body weight. Cycles within a course are separated by 23 to 27 days. No additional Mavenclad treatment is given during the next two years after completion of both courses.
Mavenclad carries boxed warnings for malignancies and fetal harm. Other serious concerns include severe lymphopenia, serious infections, herpes zoster, hepatitis reactivation, liver injury, blood-cell abnormalities, hypersensitivity, and cardiac failure. Females of reproductive potential use contraception during treatment and for six months after each course, while males take precautions to prevent pregnancy for at least 14 weeks after the last dose of each course.
Mavenclad treats relapsing forms of multiple sclerosis in adults, including relapsing-remitting disease and active secondary progressive disease.
The labeled regimen consists of two yearly treatment courses, each divided into two short dosing cycles.
The recommended cumulative dose is 3.5 mg per kg across two yearly treatment courses.
Yes. The boxed warnings concern malignancies and the risk of serious fetal harm.
Cladribine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548555/. Date Accessed October 13, 2026.
Cladribine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619038.html. Date Accessed October 13, 2026.
Cladribine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/20279. Date Accessed October 13, 2026.
Cladribine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK545307/. Date Accessed October 13, 2026.
DailyMed - MAVENCLAD (cladribine) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c75e30a-a410-40f1-b653-04d532bd9144. Date Accessed October 13, 2026.